This financial calendar lists the expected release dates of Ambu’s financial announcements for the financial year 2023/24, as well as the date of Ambu’s Annual General Meeting.
2023
| 8 NOVEMBER 2023 | Annual Report 2022/23 |
| 13 DECEMBER 2023 | Annual General Meeting 2023 |
2024
| 30 JANUARY 2024 | Earnings release Q1 2023/24 |
| 14 MAY 2024 | Earnings release Q2 2023/24 |
| 30 AUGUST 2024 | Earnings release Q3 2023/24 |
| 30 SEPTEMBER 2024 | End of fiscal year 2023/24 |
| 5 NOVEMBER 2024 | Annual Report 2023/24 |
| 4 DECEMBER 2024 | Annual General Meeting 2024 |
The deadline for the inclusion of specific items on the agenda for the Annual General Meeting 2023 is 31 October 2023.
Ambu A/S
Baltorpbakken 13
2750 Ballerup
Denmark
Tel. +45 7225 2000
CVR no.: 63 64 49 19
www.Ambu.com
CONTACT INFORMATION
Media
Tine Bjørn Schmidt
Head of Corporate Communications
tisc@ambu.com
+45 2264 0697
Investors
Anders Hjort
Head of Investor Relations
anhj@ambu.com
+45 2892 8881
ABOUT AMBU
Since 1937, Ambu has been rethinking solutions, together with healthcare professionals, to save lives and improve patient care. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia and patient monitoring solutions. Headquartered near Copenhagen in Denmark, Ambu employs around 4,500 people in Europe, North America, Latin America and Asia Pacific. For more information, please visit Ambu.com.
Attachment
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI)…
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
